New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

(2015) Eric Lawitz et al.   HEPATOLOGY

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation

(2014) D Hartwell et al.   HEALTH TECHNOLOGY ASSESSMENT

Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: Modelling the predicted impact of treatment under different scenarios

(2014) Ross J. Harris et al.   JOURNAL OF HEPATOLOGY

HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact

(2014) N. K. Martin et al.   JOURNAL OF VIRAL HEPATITIS

Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis

(2014) Roger Williams et al.   LANCET

Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection

(2014) Nezam Afdhal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

(2014) Kris V. Kowdley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma

(2013) Rebecca L. Morgan et al.   ANNALS OF INTERNAL MEDICINE

Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy

(2013) Natasha K. Martin et al.   CLINICAL INFECTIOUS DISEASES

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

(2013) Natasha K. Martin et al.   HEPATOLOGY

Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

(2013) Adriaan J. van der Meer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Estimating prevalence of injecting drug users and associated heroin-related death rates in England by using regional data and incorporating prior information

(2013) Ruth King et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY

Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons

(2013) Natasha K Martin et al.   BMJ Open

Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings

(2012) Peter Vickerman et al.   ADDICTION

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence

(2011) Katy M. E. Turner et al.   ADDICTION

Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More

(2011) B. L. Pearlman et al.   CLINICAL INFECTIOUS DISEASES

Spatial mapping of hepatitis C prevalence in recent injecting drug users in contact with services

(2011) R. J. HARRIS et al.   EPIDEMIOLOGY AND INFECTION

Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis

(2011) Ross J. Harris et al.   EUROPEAN JOURNAL OF PUBLIC HEALTH

Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care

(2011) Hamish A. Innes et al.   HEPATOLOGY

Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations

(2011) Natasha K. Martin et al.   HEPATOLOGY

Hepatitis C Infection Among Injecting Drug Users in England and Wales (1992-2006): There and Back Again?

(2009) M. J. Sweeting et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus

(2009) Amit G. Singal et al.   Clinical Gastroenterology and Hepatology

Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place

(2008) H. Hagan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management

(2008) B. J. Thomson et al.   JOURNAL OF VIRAL HEPATITIS

Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial

(2008) M. Hickman et al.   JOURNAL OF VIRAL HEPATITIS

Estimating the prevalence of ex-injecting drug use in the population

(2008) MJ Sweeting et al.   STATISTICAL METHODS IN MEDICAL RESEARCH